Clémence Henon

The share of this author’s assessed papers carrying a ⚑ flag. A concentration is a prompt for expert review — never, on its own, a determination about the person.

Collaborators, sized by shared output and coloured by their own reproducibility (green = high, red = low). Click a node to open their card. A pattern is a prompt for review, never a determination.

How this author’s assessed papers reproduced — the outcome of reproduction attempts, not a judgement of the person. Coverage is partial and grows over time.

Assessed papers (1)

• Single-cell multiomics profiling reveals heterogeneous transcriptional programs and microenvironment in DSRCTs.
  2024 L1 76/100

1 assessed by us (1 reproduced) · 108 not yet assessed — every PubMed paper on record, linked below.

• Natural history and treatment sensitivity of alveolar soft part sarcoma: A national multicenter analysis from the French sarcoma group ↗

  European Journal of Cancer · 2026 · PMID 41719753
  not yet assessed
• Abstract 6195: Spatial transcriptomics analysis reveals tumor cell plasticity and diverse tumor microenvironments in Ewing sarcoma ↗

  Cancer Research · 2026
  not yet assessed
• Abstract 643: The Sean Karl Cohort: An international single-cell RNAseq study of paired patient Ewing sarcoma specimens. ↗

  Cancer Research · 2026
  not yet assessed
• Predicting survival of patients treated with antibody–drug conjugates in early-phase clinical trials using AI-quantified 3D body composition on CT scans ↗

  Frontiers in Oncology · 2026 · PMID 42211497
  not yet assessed
• Genomic landscape of Ewing sarcoma: a pooled analysis of 538 cases and clinicopathological correlation ↗

  medRxiv · 2026
  not yet assessed
• Therapeutic advances in Tenosynovial giant cell Tumor: Targeting the CSF1/CSF1R axis ↗

  Cancer Treatment Reviews · 2025 · PMID 40020639
  not yet assessed
• Comprehensive DSRCT multi‐omics analyses unveil CACNA2D2 as a diagnostic hallmark and super‐enhancer‐driven EWSR1::WT1 signature gene ↗

  癌症：英文版 · 2025 · PMID 40088092
  not yet assessed
• Twenty-year survival of advanced gastrointestinal stromal tumours treated with imatinib: exploratory long-term follow-up of the BFR14 trial ↗

  Annals of Oncology · 2025 · PMID 40447230
  not yet assessed
• Multi‐omics profiling identified two epithelioid sarcoma molecular subtypes with distinct signaling and immune characteristics ↗

  癌症：英文版 · 2025 · PMID 41313621
  not yet assessed
• Regorafenib as maintenance therapy after first-line doxorubicin-based chemotherapy in advanced non-adipocytic soft tissue sarcomas patients: a double-blind randomised trial ↗

  Annals of Oncology · 2025 · PMID 40210087
  not yet assessed
• Clinical presentation, management and outcome of 11132 patients with liposarcoma: a population-based study from the NETSARC+ registry ↗

  The Lancet Regional Health - Europe · 2025 · PMID 40799506
  not yet assessed
• Age Does not Affect the Efficacy of Antibody Drug Conjugates, But is Associated with High-Grade Adverse Events in Patients with Cancer Enrolled in Early Phase Clinical Trials ↗

  Drugs & Aging · 2025 · PMID 40374847
  not yet assessed
• Abstract CT089: Clinical and translational results of the academic ARIANES Phase 2 basket study: Longitudinal bulk and single-cell RNAseq analyses of patient tumors identify biological correlates of response to PARP inhibitors and anti-PD-L1 therapy ↗

  Cancer Research · 2025
  not yet assessed
• Figure 5 from Replication Stress Is an Actionable Genetic Vulnerability in Desmoplastic Small Round Cell Tumors ↗

  2025
  not yet assessed
• Figure 2 from Replication Stress Is an Actionable Genetic Vulnerability in Desmoplastic Small Round Cell Tumors ↗

  2025
  not yet assessed
• Figure 4 from Replication Stress Is an Actionable Genetic Vulnerability in Desmoplastic Small Round Cell Tumors ↗

  2025
  not yet assessed
• Data from Replication Stress Is an Actionable Genetic Vulnerability in Desmoplastic Small Round Cell Tumors ↗

  2025
  not yet assessed
• Figure 6 from Replication Stress Is an Actionable Genetic Vulnerability in Desmoplastic Small Round Cell Tumors ↗

  2025
  not yet assessed
• Supplementary Data from Replication Stress Is an Actionable Genetic Vulnerability in Desmoplastic Small Round Cell Tumors ↗

  2025
  not yet assessed
• Figure 3 from Replication Stress Is an Actionable Genetic Vulnerability in Desmoplastic Small Round Cell Tumors ↗

  2025
  not yet assessed
• Supplementary Tables S1-S4 from Replication Stress Is an Actionable Genetic Vulnerability in Desmoplastic Small Round Cell Tumors ↗

  2025
  not yet assessed
• Figure 1 from Replication Stress Is an Actionable Genetic Vulnerability in Desmoplastic Small Round Cell Tumors ↗

  2025
  not yet assessed
• Liposarcomas: Natural History of 11132 Patients from the NETSARC Nationwide Registry ↗

  SSRN Electronic Journal · 2025
  not yet assessed
• Abstract 2677: Multi-omics profiling identifies two epithelioid sarcoma molecular subtypes with distinct signaling and immune characteristics ↗

  Cancer Research · 2025
  not yet assessed
• 493P Young-onset gastrointestinal cancer patients enrolled in phase I clinical trials: The experience from Gustave Roussy Cancer Center ↗

  Annals of Oncology · 2025
  not yet assessed
• Dynamic oncogene activity metabolically reprograms the tryptophan– kynurenine–AHR axis driving immune evasion and tumor progression in Ewing sarcoma ↗

  bioRxiv (Cold Spring Harbor Laboratory) · 2025
  not yet assessed
• Improved nationwide survival of sarcoma patients with a network of reference centers ↗

  Annals of Oncology · 2024 · PMID 38246351
  not yet assessed
• A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse ↗

  Annals of Oncology · 2024 · PMID 39241959
  not yet assessed
• Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 trial ↗

  The Lancet Oncology · 2024 · PMID 39127063
  not yet assessed
• Single-cell multiomics profiling reveals heterogeneous transcriptional programs and microenvironment in DSRCTs

  Cell Reports Medicine · 2024 · PMID 38781959
  L1 76/100
• Exploring the Role of Target Expression in Treatment Efficacy of Antibody–Drug Conjugates (ADCs) in Solid Cancers: A Comprehensive Review ↗

  Current Oncology Reports · 2024 · PMID 39066847
  not yet assessed
• Replication Stress Is an Actionable Genetic Vulnerability in Desmoplastic Small Round Cell Tumors ↗

  Cancer Research · 2024 · PMID 39412947
  not yet assessed
• Is Local Ablative Stereotactic Radiation Therapy a Valuable Rescue Strategy for Time on Drug in Patients Enrolled in Phase I Trials? ↗

  International Journal of Radiation Oncology*Biology*Physics · 2024 · PMID 39128580
  not yet assessed
• Vena cava leiomyosarcoma surgery results in a retrospective cohort of 41 patients from two centers ↗

  Journal of Surgical Oncology · 2024 · PMID 38973131
  not yet assessed
• 55O IMADGIST: A randomized study of 6 vs 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse ↗

  ESMO Open · 2024
  not yet assessed
• 52O Resistance to imatinib induced by treatment interruption in advanced GIST: Long-term outcome of the randomized BFR14 study ↗

  ESMO Open · 2024
  not yet assessed
• 87P Characteristics and outcomes of 11 patients with myoepithelial tumors: The Gustave Roussy experience ↗

  ESMO Open · 2024
  not yet assessed
• Abstract 6406: Clinical and translational results of the academic ARIANES Phase 2 basket study: Longitudinal single-cell analysis of patient tumors identifies biological correlates of response to PARP inhibitors and anti-PD-L1 therapy ↗

  Cancer Research · 2024
  not yet assessed
• Monocyte/lymphocyte ratio to predict immunoradiotherapy response in patients with advanced pretreated sarcoma. ↗

  Journal of Clinical Oncology · 2024
  not yet assessed
• LBA79 LENVAGIST: A multicentre, comparative, placebo (P)-controlled, double-blinded, phase II study of the efficacy of Lenvatinib (L) in patients with advanced GIST after failure of imatinib and sunitinib ↗

  Annals of Oncology · 2024
  not yet assessed
• Abstract B083: The use of liquid biopsy in patients with advanced pancreatic cancer (PDAC) to guide enrollment in phase I clinical trials ↗

  Cancer Research · 2024
  not yet assessed
• A Comprehensive Review on the Role of Lurbinectedin in Soft Tissue Sarcomas ↗

  Current Treatment Options in Oncology · 2024 · PMID 38324075
  not yet assessed
• Abstract 6932: Single-cell multiomics profiling reveals heterogeneous transcriptional programs and microenvironment in desmoplastic small round cell tumors ↗

  Cancer Research · 2024
  not yet assessed
• Abstract 6438: Subcutaneous fat mass predicts progression-free survival in patients treated with antibody-drug-conjugates in early-phase clinical trials ↗

  Cancer Research · 2024
  not yet assessed
• 657P Prospective validation of the T cell engager (TCE) score in patients treated with bispecific CD3 TCE antibodies in phase I clinical trials ↗

  Annals of Oncology · 2024
  not yet assessed
• 1749P Vertebral MRI in the screening for bone metastasis in myxoid liposarcoma: Is it justified? ↗

  Annals of Oncology · 2024
  not yet assessed
• 156P Liver metastases correlate with shortened survival and increased dissociate response in patients treated with T cell engagers ↗

  Immuno-Oncology Technology · 2024
  not yet assessed
• Fibroblasts generate topographical cues that steer cancer cell migration ↗

  Science Advances · 2023 · PMID 37585527
  not yet assessed
• Efficacy of immune checkpoint inhibitors in alveolar soft-part sarcoma: results from a retrospective worldwide registry ↗

  ESMO Open · 2023 · PMID 38016251
  not yet assessed
• Natural history and treatment efficacy in an ambispective case series of NTRK-rearranged mesenchymal tumors ↗

  ESMO Open · 2023 · PMID 37054503
  not yet assessed
• Desmoid-type fibromatosis: Current therapeutic strategies and future perspectives ↗

  Cancer Treatment Reviews · 2023 · PMID 38159438
  not yet assessed
• Systemic Therapy in Advanced Pleomorphic Liposarcoma: a Comprehensive Review ↗

  Current Treatment Options in Oncology · 2023 · PMID 37843627
  not yet assessed
• Antibody drug conjugates in older patients: State of the art ↗

  Critical Reviews in Oncology/Hematology · 2023 · PMID 38007063
  not yet assessed
• Evolution of Patterns of Care and Outcomes in the Real-Life Setting for Patients with Metastatic GIST Treated in Three French Expert Centers over Three Decades ↗

  Cancers · 2023 · PMID 37686582
  not yet assessed
• 1659P The use of liquid biopsy in patients with advanced pancreatic cancer (PDAC) to guide enrollment in phase I clinical trials ↗

  Annals of Oncology · 2023
  not yet assessed
• Data from PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer ↗

  2023
  not yet assessed
• Supplementary data from PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer ↗

  2023
  not yet assessed
• Supplementary Table from PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer ↗

  2023
  not yet assessed
• Supplementary Figure from PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer ↗

  2023
  not yet assessed
• Supplementary Figure from PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer ↗

  2023
  not yet assessed
• Data from PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer ↗

  2023
  not yet assessed
• Supplementary Figure from PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer ↗

  2023
  not yet assessed
• Supplementary data from PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer ↗

  2023
  not yet assessed
• Supplementary data from PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer ↗

  2023
  not yet assessed
• Supplementary Figure from PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer ↗

  2023
  not yet assessed
• Supplementary Figure from PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer ↗

  2023
  not yet assessed
• Supplementary Table from PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer ↗

  2023
  not yet assessed
• Supplementary data from PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer ↗

  2023
  not yet assessed
• Supplementary data from PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer ↗

  2023
  not yet assessed
• Supplementary data from PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer ↗

  2023
  not yet assessed
• Supplementary data from PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer ↗

  2023
  not yet assessed
• Supplementary data from PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer ↗

  2023
  not yet assessed
• Supplementary data from PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer ↗

  2023
  not yet assessed
• Supplementary Figure from PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer ↗

  2023
  not yet assessed
• Supplementary data from PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer ↗

  2023
  not yet assessed
• Traitement par imatinib des tumeurs stromales gastro-intestinales, 20 ans après ↗

  Bulletin de l Académie Nationale de Médecine · 2023
  not yet assessed
• Prediction of brain metastases progression and overall survival in patients with metastatic non-small cell lung cancer treated by immune checkpoint inhibitors using a radiomic model. ↗

  Journal of Clinical Oncology · 2023
  not yet assessed
• Risks and benefits of phase 1 clinical trials for patients with relapsed or refractory lymphoma, from 2008 to 2023 ↗

  Hematological Oncology · 2023 · PMID 39112237
  not yet assessed
• 1845P Exclusion of patients with psychiatric disorders from early phase oncology trials: A limited access to innovation? ↗

  Annals of Oncology · 2023
  not yet assessed
• 516P Building a new prognostic score for patients with central nervous system (CNS) tumors enrolled in early phase clinical trials ↗

  Annals of Oncology · 2023
  not yet assessed
• 1933P Perioperative chemotherapy could reduce the risk of recurrence in resected leiomyosarcoma of the vena cava (LMS-VC): A retrospective bi-centric series on 41 patients ↗

  Annals of Oncology · 2023
  not yet assessed
• Safety and efficacy of antibody drug conjugates in older patients with solid tumors ↗

  Journal of Geriatric Oncology · 2023
  not yet assessed
• Exploration of Desmoplastic Small Round Cell Tumors Cellular and Molecular Heterogeneity ↗

  2023
  not yet assessed
• Exploration of Desmoplastic Small Round Cell Tumors Cellular and Molecular Heterogeneity ↗

  2023
  not yet assessed
• Oncogenic chimeric transcription factors drive tumor-specific transcription, processing, and translation of silent genomic regions ↗

  Molecular Cell · 2022 · PMID 35550257
  not yet assessed
• Single‐agent gemcitabine in patients with advanced, pre‐treated angiosarcoma: A multicenter, retrospective study ↗

  Cancer Medicine · 2022 · PMID 35971325
  not yet assessed
• Fibroblasts generate topographical cues that steer cancer cell migration ↗

  bioRxiv (Cold Spring Harbor Laboratory) · 2022
  not yet assessed
• Abstract 6277: Identification of ATR inhibitors as therapeutic opportunities in Desmoplastic small round cell tumors ↗

  Cancer Research · 2022
  not yet assessed
• PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer ↗

  Cancer Research · 2021 · PMID 33888468
  not yet assessed
• Retrospective world-wide registry on the efficacy of immune checkpoint inhibitors in alveolar soft part sarcoma: Updated results from sixty patients. ↗

  Journal of Clinical Oncology · 2021
  not yet assessed
• Activity of erlotinib in patients (pts) with advanced chordoma: A retrospective study. ↗

  Journal of Clinical Oncology · 2021
  not yet assessed
• Activity of single-agent gemcitabine in patients (pts) with advanced angiosarcoma: A retrospective study. ↗

  Journal of Clinical Oncology · 2021
  not yet assessed
• Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19 ↗

  Cell · 2020 · PMID 32810439
  not yet assessed
• Immune responses during COVID-19 infection ↗

  OncoImmunology · 2020 · PMID 32939324
  not yet assessed
• Combination Treatments with Immunotherapy in Brain Metastases Patients ↗

  Future Oncology · 2020 · PMID 32412817
  not yet assessed
• PBRM1 deficiency in cancer is synthetic lethal with DNA repair inhibitors

  HAL (Le Centre pour la Communication Scientifique Directe) · 2020
  not yet assessed
• Outcome of Patients with Non–Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors ↗

  Journal of Thoracic Oncology · 2019 · PMID 30780002
  not yet assessed
• Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor ↗

  Annals of Oncology · 2019 · PMID 31114851
  not yet assessed
• Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors ↗

  European Journal of Cancer · 2019 · PMID 31203193
  not yet assessed
• Quality of Life During Chemotherapy for Breast Cancer in a West African Population in Dakar, Senegal: A Prospective Study ↗

  Journal of Global Oncology · 2019 · PMID 31322991
  not yet assessed
• Comparison of molecular profiles between primary tumour and matched metastasis in non-small cell lung cancer ↗

  Annals of Oncology · 2019
  not yet assessed
• PARP inhibition enhances tumor cell–intrinsic immunity in ERCC1-deficient non–small cell lung cancer ↗

  Journal of Clinical Investigation · 2018 · PMID 30589644
  not yet assessed
• Impact of central nervous system (CNS) involvement in advanced non-small cell lung cancer (NSCLC) patients (pts) treated with immune checkpoint inhibitors (ICI). ↗

  Journal of Clinical Oncology · 2018
  not yet assessed
• MA08.09 Impact of Brain Metastases in Immune Checkpoint Inhibitors (ICI) Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients ↗

  Journal of Thoracic Oncology · 2018
  not yet assessed
• Prognostic factors in non-small cell lung cancer (NSCLC) patients (pts) with brain metastases (BM) treated with immune checkpoint inhibitors (ICI) ↗

  Annals of Oncology · 2018
  not yet assessed
• Patient-reported tolerability of adverse events in phase 1 trials ↗

  ESMO Open · 2017 · PMID 28761740
  not yet assessed
• P2.07-005 Impact of Baseline Leptomeningeal and Brain Metastases on Immunotherapy Outcomes in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients ↗

  Journal of Thoracic Oncology · 2017
  not yet assessed
• Cytidine Deaminase Activity Assessment to Select Perioperative Chemotherapy Regimen in Localized Bladder Cancer ↗

  Clinical Genitourinary Cancer · 2017 · PMID 28233698
  not yet assessed
• Les actualités marquantes du congrès Targeted Anticancer Therapies — TAT 2016 ↗

  ONCOLOGIE · 2016
  not yet assessed